NEW YORK – Molecular analysis firm Aegea Biotechnologies announced Tuesday it has entered into a collaboration agreement with Tauriga Sciences to develop a rapid multiplexed PCR-based test for SARS-CoV-2.
The test, which is being developed by Aegea, will be designed "to have superior sensitivity and selectivity," and will measure the virus from nasal or other swabs, the companies said. The test will also use Aegea's technologies, which can detect targets with single-nucleotide resolution, to differentiate between different strains of the virus.